NCT01689025View on ClinicalTrials.gov

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
InflammationSystemic Lupus Erythematosus
Interventions
DRUG

NNC0114-0006

Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.

DRUG

placebo

Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.

Trial Locations (5)

6720

Szeged

11000

Belgrade

77034

Novo Nordisk Clinical Trial Call Center, Houston

92093

Novo Nordisk Clinical Trial Call Center, La Jolla

60-218

Poznan

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY